147 related articles for article (PubMed ID: 22040817)
1. [Frontiers in vitamin D; basic Research and clinical application. Effect of active vitamin D3 on osteoporosis].
Yamauchi M; Sugimoto T
Clin Calcium; 2011 Nov; 21(11):17-24. PubMed ID: 22040817
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
[TBL] [Abstract][Full Text] [Related]
3. [Vitamin D and calcium for the treatment of osteoporosis].
Inoue D
Nihon Rinsho; 2009 May; 67(5):967-74. PubMed ID: 19432118
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic concepts in the treatment of postmenopausal osteoporosis].
Leidig-Bruckner G; Ziegler R
Ther Umsch; 1994 Nov; 51(11):737-47. PubMed ID: 7839332
[TBL] [Abstract][Full Text] [Related]
5. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
Hosoi T;
Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
[TBL] [Abstract][Full Text] [Related]
6. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Anić B; Grazio S
Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
[TBL] [Abstract][Full Text] [Related]
7. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
Endo I; Matsumoto T
Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
9. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
10. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
11. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
12. [Drug therapy for prevention of falls and fractures].
Ringe JD
Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
[TBL] [Abstract][Full Text] [Related]
13. Is bone mineral density predictive of fracture risk reduction?
Cefalu CA
Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
[TBL] [Abstract][Full Text] [Related]
14. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
Bone HG; Santora AC; Chattopadhyay A; Liberman U
J Bone Miner Res; 2005 Nov; 20(11):2064-5. PubMed ID: 16234982
[No Abstract] [Full Text] [Related]
15. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
17. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
18. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
19. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
20. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
